Compare Biogen Inc (BIIB) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Prologis Inc — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while Prologis Inc trades at $142.49 (market cap $132.85B). The key difference: Prologis Inc is far larger — about 4.7× Biogen Inc's market cap, and Prologis Inc pays a 3% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | PLD | |
|---|---|---|
Market Cap | $28.34B | $132.85B |
Sector | Health | Real Estate |
52-Week High | $216.63 | $148.74 |
52-Week Low | $122.68 | $104.08 |
Enterprise Value | $30.62B | $166.72B |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Prologis (PLD) trades at $142.16, up 0.92% today, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.05 exceeding expectations of $0.806. Recent news highlights expansion into data centers and a rejected $16.9 billion bid for Segro, indicating aggressive growth ambitions. Cash flow trends show operational strength despite a net outflow in 2025, while debt-to-asset ratios have risen to 37.2%.
The outlook remains positive with a consensus price target of $155.20, offering ~9% upside. Key risks include rising leverage, execution challenges in new segments, and macroeconomic sensitivity. Institutional sentiment is bullish, but investors should monitor debt levels and integration of strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
